Literature DB >> 302279

Characterization of suppressive immunoglobulin-binding factor (IBF). I. Production of IBF by a theta-positive lymphoma (L-5178-Y).

W H Fridman, A Guimezanes, R H Gisler.   

Abstract

L-5178-Y, a theta-positive, Fc receptor-bearing mouse thymoma cell line spontaneously releases immunoglobulin-binding factor (IBF) upon short-term incubation in vitro. IBF produced by L-5178-Y cells is identical in its biologic activity with IBF produced by Fc receptor positive alloantigen-activated T cells. It suppresses the in vitro plaque response of mouse spleen cells to sheep erythrocytes by interfering mainly with the late phase of the generation of antibody-forming cells. Therefore, L-5178-Y thymoma affords a homogeneous source of IBF in sufficient quantities for the study of its biochemical nature and the mechanism by which it interferes with cells participating in antibody synthesis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Relationship between a spleen-derived immunosuppressive peptide 'SDIP' and the 'Facteur thymique sérique' (FTS): biochemical and biological comparison of the two factors.

Authors:  M Lenfant; L Millerioux; I Blazsek; N Duchange
Journal:  Immunology       Date:  1983-04       Impact factor: 7.397

Review 2.  Recent studies on the regulation of IgE antibody synthesis in experimental animals and man.

Authors:  D H Katz
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

3.  Functional and biochemical characterization of a secreted I-J(+) suppressor factor that binds to immunoglobulin.

Authors:  M J Daley; M Nakamura; M L Gefter
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

4.  The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice.

Authors:  K J Weinhold; L T Goldstein; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.